SuperworthChemours CC
- Market cap
- $1.9B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $5.8B
- −1% on a year ago
- Net margin
- −5.2%
- Free cash flow yield
- n/m
- not a meaningful number
Chemours trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $5.8B over the last twelve months, down 1% on a year earlier with a −5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.5B−16% | $1.4B+2% | $1.4B−12% | $1.6B−6% | $1.5B+1% | $1.4B−1% | $1.4B+0% | $1.6B+4% | $1.5B−1% | $1.3B−2% | $1.4B+1% | $1.6B−2% | |
| Cost of revenue | $1.2B−9% | $1.1B−2% | $1.1B−9% | $1.2B−0% | $1.2B−1% | $1.1B−2% | $1.1B+5% | $1.3B+7% | $1.3B+3% | $1.2B+7% | $1.2B+3% | $1.3B−2% |
| Gross profit | $273M−37% | $255M+26% | $284M−23% | $308M−25% | $286M+5% | $265M+4% | $236M−17% | $278M−10% | $233M−19% | n/a | $212M−10% | $286M+3% |
| R&D | $28M−13% | $26M−13% | $28M+8% | $26M−7% | $29M+4% | $26M+0% | $27M−4% | $28M+8% | $26M−10% | n/a | $26M−4% | $27M−4% |
| SG&A | $165M+18% | $223M+27% | $137M+11% | $154M−80% | $137M−17% | $170M−24% | $123M−10% | $424M+175% | $109M−20% | n/a | $147M+20% | $469M+11% |
| $13M−95% | −$6M−33% | $115M−34% | $125M | $19M+46% | $1M | $53M−54% | −$192M | $94M+395% | n/a | $26M−51% | −$213M+11% | |
| Interest expense | $55M+34% | $63M+58% | $63M+50% | $66M+38% | $68M+24% | $67M+6% | $66M+5% | $67M+2% | $68M+0% | n/a | $69M+5% | $68M+2% |
| Pre-tax income | $13M−96% | −$71M+3% | $70M−60% | $69M | −$32M | $1M | $0 | −$248M | $51M | n/a | −$22M | −$1M−100% |
| $1M−98% | −$53M | $16M−43% | $9M | $0 | $17M | $5M−69% | $131M+1356% | −$9M | n/a | $7M+40% | $273M+108% | |
| Net income | $12M−95% | −$18M−81% | $54M−63% | $60M | −$32M | −$11M−39% | −$5M | −$380M | $46M | −$47M+327% | −$29M+480% | −$274M−28% |
| $0.08−95% | −$0.12−82% | $0.36−63% | $0.39 | −$0.22 | −$0.08−33% | −$0.03 | −$2.53 | $0.31 | −$0.31+288% | −$0.19+533% | −$1.81−29% | |
| 150.2M−5% | 148.9M−1% | 150.1M−1% | 150.1M+1% | 149.7M−0% | 149.8M+1% | 149.9M−0% | 150.2M+0% | 150.8M+1% | n/a | 150.8M+1% | 151.2M+1% |
Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
R&D: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
SG&A: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them. 46 periods, Q2 FY14 to Q2 FY26: not printed by the filing, worked out from its own lines.
Interest expense: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Income tax: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q4 FY14 to Q4 FY22: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY14 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY15 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest Chemours' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CCChemours | $1.9B | n/m | 12.5× | 0.3× | −1% | −5.2% | |
| ROGRogers | $2.2B | 71.4× | 34.3× | 2.7× | +5% | 3.7% | |
| NGVTIngevity | $2.4B | 47.4× | 19.9× | 2.1× | −4% | 4.7% | |
| IOSPInnospec | $2.4B | 20.1× | 22.3× | 1.3× | +3% | 6.6% | |
| FULFuller H B | $2.7B | 13.8× | 22.9× | 0.8× | +1% | 5.6% | |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | 4.2× | +10% | 13.2% | |
| CRONCronos | $1.2B | 16.8× | 25.0× | 6.9× | +37% | 39.1% | |
| AVNTAvient | $3.8B | 22.2× | 20.2× | 1.1× | +2% | 5.1% | |
| CBTCabot | $3.8B | 20.8× | 14.4× | 1.0× | −5% | 5.2% | |
| FTKFlotek Industries | $865.7M | 24.1× | 27.6× | 3.0× | +37% | 13.0% | |
| CSWCSW Industrials | $4.8B | 40.6× | 34.7× | 4.1× | +28% | 10.3% | |
| Peer median | $2.6B | 23.2× | 23.9× | 2.4× | +4% | 6.1% |
More on Chemours
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .